天美传媒

Inflammatory markers are biological substances, typically proteins or cells, that indicate the presence, intensity, or progression of inflammation in the body. Inflammation is a natural immune response to infection, injury, or harmful stimuli, serving as a protective mechanism to eliminate threats and initiate healing. However, chronic or excessive inflammation contributes to numerous health conditions, including cardiovascular disease, autoimmune disorders, diabetes, and certain cancers. Measuring inflammatory markers allows clinicians and researchers to assess immune activity, monitor disease progression, and guide therapeutic interventions [1,2].

Discussion

Inflammatory markers can be broadly categorized into acute-phase proteins, cytokines, and cellular markers. Acute-phase proteins, such as C-reactive protein (CRP) and fibrinogen, are produced by the liver in response to pro-inflammatory cytokines. CRP, in particular, is widely used in clinical settings as a sensitive indicator of systemic inflammation. Elevated CRP levels are associated with increased risk of cardiovascular events, infections, and chronic inflammatory conditions. Cytokines, including interleukins (IL-1, IL-6), tumor necrosis factor-alpha (TNF-α), and interferons, act as signaling molecules to regulate immune responses, recruit immune cells, and amplify inflammation. Dysregulated cytokine activity is implicated in autoimmune diseases, sepsis, and cytokine storm syndromes [3-6].

Cellular markers involve changes in leukocyte populations or activation states. Elevated neutrophil counts, altered lymphocyte ratios, or the presence of activated monocytes may reflect ongoing inflammation or immune dysregulation. Advanced techniques, such as flow cytometry, allow precise quantification of these cellular markers, providing insights into disease mechanisms and therapeutic responses [7,8].

Inflammatory markers have important diagnostic, prognostic, and therapeutic implications. For example, high-sensitivity CRP (hs-CRP) testing helps assess cardiovascular risk in otherwise healthy individuals. In autoimmune diseases like rheumatoid arthritis or inflammatory bowel disease, monitoring cytokine levels and acute-phase proteins guides treatment efficacy and disease activity. Similarly, inflammatory markers are valuable in research on mental health, as emerging evidence links chronic low-grade inflammation to depression, anxiety, and neurodegenerative disorders [9,10].

Several factors influence inflammatory marker levels, including genetics, age, lifestyle, infections, and comorbid conditions. Obesity, smoking, chronic stress, and poor diet can contribute to sustained low-grade inflammation, increasing disease susceptibility. Conversely, regular exercise, balanced nutrition, stress management, and adequate sleep are associated with lower systemic inflammation and improved overall health.

Conclusion

Inflammatory markers are critical tools for assessing immune system activity and identifying pathological processes. By reflecting acute or chronic inflammation, they help guide diagnosis, monitor disease progression, and evaluate therapeutic responses across a range of medical conditions, including cardiovascular, autoimmune, metabolic, and neuropsychiatric disorders. While inflammation is a protective mechanism, persistent or uncontrolled inflammatory responses contribute to significant morbidity. Incorporating the measurement of inflammatory markers into clinical practice, along with lifestyle modifications and targeted therapies, can improve patient outcomes, promote preventive health, and advance our understanding of the complex interactions between the immune system and overall well-being.

References

• Flavie W, Charles F (2017) . Schizophr Bull 43:32-43.

  , , .

• Siu WT, Wayne HT (2020) . Int Clin Psychopharmacol 35: 293-299.

  , , .

• Charles F (2019) . Psychol Med 49: 2639-2645.

  , , .

• Renaud J, Kenneth H, Matthew H, Jerome B, Flavie W, et al. (2016) . Schizophr Bull 42: 1124-1134.

  , , .

• Marcella M, Pantelis L, Charles F, Flavie W, Frank L, et al. (2021) . Schizophr Bull 47: 237-248.

  , , .

• kenneth H (2017) . Balkan Med J 34: 504-513.

  , , .

• Gras A, Amad A, Thomas P, Jardri R (2014) . Encephale 40: 431-438.

  , , .

• Franco DM, Cesare D, Gabriella G, Andrea P (2015) . Int J Psychoanal 96: 293-318.

  , , .

• Shusaku O, Hidetomo M, Tomotaka S, Keiko B, Tadashi U, et al. (2021) . Acta Neurol Scand 143: 538-544.

  , , .

• Kirk R, John F, Frances S (2011) . Clin Psychol Psychother 18: 524-534.

  , , .